Developments X4 Pharma’s mavorixafor gets EC orphan drug designation for WHIM syndrome The European Commission (EC) granted X4 Pharmaceuticals’ (NASDAQ:XFOR) mavorixafor orphan drug designation for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and... August 1, 2019